---
document_datetime: 2026-01-19 17:25:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rybelsus.html
document_name: rybelsus.html
version: success
processing_time: 0.3680834
conversion_datetime: 2026-01-20 20:07:40.365881
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Rybelsus

# Rybelsus

[RSS](/en/individual-human-medicine.xml/67289)

##### Authorised

This medicine is authorised for use in the European Union

semaglutide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rybelsus](#news-on)
- [Preventing medication errors](#preventing-medication-errors-78585)
- [More information on Rybelsus](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rybelsus is a medicine used to control blood glucose (sugar) levels in adults whose type 2 diabetes is not controlled well enough. It can be used on its own when metformin (another medicine for diabetes) cannot be used, or in combination with other diabetes medicines. It should be used with an appropriate diet and physical exercise.

Rybelsus contains the active substance semaglutide.

Expand section

Collapse section

## How is Rybelsus used?

Rybelsus is available as tablets to be taken by mouth once a day and can only be obtained with a prescription. Patients should start on the lowest dose, which is increased to a maintenance dose after one month. After at least one month on this dose, the dose can be increased to the next higher dose if needed.

For more information about using Rybelsus, see the package leaflet or contact your doctor or pharmacist.

## How does Rybelsus work?

Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body cannot use insulin effectively. The result is a high level of glucose in the blood.

The active substance in Rybelsus, semaglutide, is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

## What benefits of Rybelsus have been shown in studies?

Rybelsus was effective at controlling blood glucose levels in 7 main studies involving a total of over 5,500 patients with type 2 diabetes.

Depending on the dose, Rybelsus lowered HbA1c (showing improved blood glucose control) by between 0.6 and 1.4 percentage points. The results compared favourably with those with three other diabetes treatments empagliflozin, sitagliptin or liraglutide, which led to reductions of 0.9, 0.8, 0.9 percentage points, respectively. Rybelsus was also more effective than placebo (a dummy treatment).

In addition to better controlled blood glucose, patients taking Rybelsus had a beneficial reduction in body weight after 6 months. A further study in close to 3,200 patients suggested that Rybelsus may reduce the number of heart attacks and strokes compared to placebo; however, the difference was not statistically significant (it may be due to chance).

## What are the risks associated with Rybelsus?

For the full list of side effects and restrictions of Rybelsus, see the package leaflet.

The most common side effects with Rybelsus (which may affect more than 1 in 10 people) include nausea (feeling sick), diarrhoea and low blood sugar levels (when used with insulin or a sulphonylurea).

## Why is Rybelsus authorised in the EU?

Rybelsus is effective at controlling blood glucose levels in patients with type 2 diabetes and can also help patients reduce their weight. The most common side effects with Rybelsus affect the digestive system; the side effects are generally manageable and similar to those with an authorised injectable form of semaglutide (Ozempic).

As with the injectable form, there is a risk that Rybelsus could worsen some patients' diabetic retinopathy (damage to the retina in the eye). Patients with this condition will therefore be monitored carefully.

The European Medicines Agency concluded that Rybelsus' benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rybelsus?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rybelsus have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rybelsus are continuously monitored. Side effects reported with Rybelsus are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rybelsus

Rybelsus received a marketing authorisation valid throughout the EU on on 3 April 2020.

Rybelsus : EPAR - Medicine overview

Reference Number: EMA/62316/2020

English (EN) (104.42 KB - PDF)

**First published:** 27/05/2020

**Last updated:** 21/08/2025

[View](/en/documents/overview/rybelsus-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-847)

български (BG) (135.5 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/bg/documents/overview/rybelsus-epar-medicine-overview_bg.pdf)

español (ES) (110.76 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/es/documents/overview/rybelsus-epar-medicine-overview_es.pdf)

čeština (CS) (133.07 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/cs/documents/overview/rybelsus-epar-medicine-overview_cs.pdf)

dansk (DA) (109.3 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/da/documents/overview/rybelsus-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.64 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/de/documents/overview/rybelsus-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.49 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/et/documents/overview/rybelsus-epar-medicine-overview_et.pdf)

ελληνικά (EL) (135.78 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/el/documents/overview/rybelsus-epar-medicine-overview_el.pdf)

français (FR) (112.51 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/fr/documents/overview/rybelsus-epar-medicine-overview_fr.pdf)

hrvatski (HR) (132.48 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/hr/documents/overview/rybelsus-epar-medicine-overview_hr.pdf)

italiano (IT) (109.09 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/it/documents/overview/rybelsus-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/lv/documents/overview/rybelsus-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (132.27 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/lt/documents/overview/rybelsus-epar-medicine-overview_lt.pdf)

magyar (HU) (130.83 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/hu/documents/overview/rybelsus-epar-medicine-overview_hu.pdf)

Malti (MT) (134.42 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/mt/documents/overview/rybelsus-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.33 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/nl/documents/overview/rybelsus-epar-medicine-overview_nl.pdf)

polski (PL) (124.76 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/pl/documents/overview/rybelsus-epar-medicine-overview_pl.pdf)

português (PT) (111.63 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/pt/documents/overview/rybelsus-epar-medicine-overview_pt.pdf)

română (RO) (128.77 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/ro/documents/overview/rybelsus-epar-medicine-overview_ro.pdf)

slovenčina (SK) (132.49 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/sk/documents/overview/rybelsus-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.18 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/sl/documents/overview/rybelsus-epar-medicine-overview_sl.pdf)

Suomi (FI) (108.07 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/fi/documents/overview/rybelsus-epar-medicine-overview_fi.pdf)

svenska (SV) (109.13 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

21/08/2025

[View](/sv/documents/overview/rybelsus-epar-medicine-overview_sv.pdf)

Rybelsus : EPAR - Risk management plan

English (EN) (2.58 MB - PDF)

**First published:** 27/05/2020

**Last updated:** 28/11/2024

[View](/en/documents/rmp-summary/rybelsus-epar-risk-management-plan_en.pdf)

## Product information

Rybelsus : EPAR - Product information

English (EN) (701.82 KB - PDF)

**First published:** 27/05/2020

**Last updated:** 19/01/2026

[View](/en/documents/product-information/rybelsus-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-761)

български (BG) (950.61 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/bg/documents/product-information/rybelsus-epar-product-information_bg.pdf)

español (ES) (758.83 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/es/documents/product-information/rybelsus-epar-product-information_es.pdf)

čeština (CS) (852.73 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/cs/documents/product-information/rybelsus-epar-product-information_cs.pdf)

dansk (DA) (751.13 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/da/documents/product-information/rybelsus-epar-product-information_da.pdf)

Deutsch (DE) (798.77 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/de/documents/product-information/rybelsus-epar-product-information_de.pdf)

eesti keel (ET) (748.65 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/et/documents/product-information/rybelsus-epar-product-information_et.pdf)

ελληνικά (EL) (978.23 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/el/documents/product-information/rybelsus-epar-product-information_el.pdf)

français (FR) (727.34 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/fr/documents/product-information/rybelsus-epar-product-information_fr.pdf)

hrvatski (HR) (817 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/hr/documents/product-information/rybelsus-epar-product-information_hr.pdf)

íslenska (IS) (747.96 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/is/documents/product-information/rybelsus-epar-product-information_is.pdf)

italiano (IT) (720.02 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/it/documents/product-information/rybelsus-epar-product-information_it.pdf)

latviešu valoda (LV) (896.92 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/lv/documents/product-information/rybelsus-epar-product-information_lv.pdf)

lietuvių kalba (LT) (862.88 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/lt/documents/product-information/rybelsus-epar-product-information_lt.pdf)

magyar (HU) (892.5 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/hu/documents/product-information/rybelsus-epar-product-information_hu.pdf)

Malti (MT) (949.22 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/mt/documents/product-information/rybelsus-epar-product-information_mt.pdf)

Nederlands (NL) (721.02 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/nl/documents/product-information/rybelsus-epar-product-information_nl.pdf)

norsk (NO) (708.4 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/no/documents/product-information/rybelsus-epar-product-information_no.pdf)

polski (PL) (916.94 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/pl/documents/product-information/rybelsus-epar-product-information_pl.pdf)

português (PT) (732.13 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/pt/documents/product-information/rybelsus-epar-product-information_pt.pdf)

română (RO) (897.18 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/ro/documents/product-information/rybelsus-epar-product-information_ro.pdf)

slovenčina (SK) (830.42 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/sk/documents/product-information/rybelsus-epar-product-information_sk.pdf)

slovenščina (SL) (886.77 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/sl/documents/product-information/rybelsus-epar-product-information_sl.pdf)

Suomi (FI) (769.31 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/fi/documents/product-information/rybelsus-epar-product-information_fi.pdf)

svenska (SV) (739.9 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

19/01/2026

[View](/sv/documents/product-information/rybelsus-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249026 16/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rybelsus : EPAR - All Authorised presentations

English (EN) (41.91 KB - PDF)

**First published:** 27/05/2020

**Last updated:** 18/10/2024

[View](/en/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-431)

български (BG) (68.63 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/bg/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_bg.pdf)

español (ES) (37.2 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/es/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.57 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/cs/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.57 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/da/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.87 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/de/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.3 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/et/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.58 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/el/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_el.pdf)

français (FR) (34.52 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/fr/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (50.94 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/hr/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.85 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/is/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.73 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/it/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.38 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/lv/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.09 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/lt/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.89 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/hu/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (51.51 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/mt/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.58 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/nl/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.67 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/no/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.86 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/pl/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_pl.pdf)

português (PT) (45.01 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/pt/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.62 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/ro/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.09 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/sk/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.82 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/sl/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.13 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/fi/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (41.13 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

18/10/2024

[View](/sv/documents/all-authorised-presentations/rybelsus-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rybelsus Active substance semaglutide International non-proprietary name (INN) or common name semaglutide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ06

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in combination with other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

## Authorisation details

EMA product number EMEA/H/C/004953 Marketing authorisation holder

Novo Nordisk A/S

Novo Alle

Opinion adopted 30/01/2020 Marketing authorisation issued 03/04/2020 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rybelsus : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (172.36 KB - PDF)

**First published:** 08/07/2025

**Last updated:** 19/01/2026

[View](/en/documents/procedural-steps-after/rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rybelsus : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (198.09 KB - PDF)

**First published:** 10/06/2020

**Last updated:** 08/07/2025

[View](/en/documents/procedural-steps-after/rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rybelsus-EMEA-H-C-PSUSA-00010671-202205 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/193544/2023

English (EN) (105.81 KB - PDF)

**First published:** 03/05/2023

[View](/en/documents/scientific-conclusion/rybelsus-emea-h-c-psusa-00010671-202205-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Rybelsus-EMEA-H-C-PSUSA-00010671-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/114770/2021

English (EN) (150.06 KB - PDF)

**First published:** 10/12/2021

[View](/en/documents/scientific-conclusion/rybelsus-emea-h-c-psusa-00010671-202005-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Rybelsus : EPAR - Public assessment report

Adopted

Reference Number: EMA/95374/2020

English (EN) (4.28 MB - PDF)

**First published:** 27/05/2020

**Last updated:** 27/07/2020

[View](/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rybelsus

Adopted

Reference Number: EMA/43724/2020

English (EN) (158.36 KB - PDF)

**First published:** 31/01/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rybelsus_en.pdf)

#### News on Rybelsus

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-june-2025) 06/06/2025

[PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy](/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) 06/06/2025

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-january-2025) 17/01/2025

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020) 31/01/2020

[First oral GLP-1 treatment for type 2 diabetes](/en/news/first-oral-glp-1-treatment-type-2-diabetes) 31/01/2020

#### Preventing medication errors

Rybelsus: Risk of medication error due to new tablet formulation

Reference Number: EMA/141235/2024

English (EN) (203.05 KB - PDF)

**First published:** 01/08/2025

[View](/en/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_en.pdf)

[Other languages (22)](#file-language-dropdown-638)

български (BG) (252.46 KB - PDF)

**First published:**

01/08/2025

[View](/bg/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_bg.pdf)

español (ES) (213.3 KB - PDF)

**First published:**

01/08/2025

[View](/es/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_es.pdf)

čeština (CS) (237.36 KB - PDF)

**First published:**

01/08/2025

[View](/cs/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_cs.pdf)

dansk (DA) (214.93 KB - PDF)

**First published:**

01/08/2025

[View](/da/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_da.pdf)

Deutsch (DE) (217.85 KB - PDF)

**First published:**

01/08/2025

[View](/de/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_de.pdf)

eesti keel (ET) (211.9 KB - PDF)

**First published:**

01/08/2025

[View](/et/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_et.pdf)

ελληνικά (EL) (255.11 KB - PDF)

**First published:**

01/08/2025

[View](/el/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_el.pdf)

français (FR) (214.11 KB - PDF)

**First published:**

01/08/2025

[View](/fr/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_fr.pdf)

hrvatski (HR) (246.53 KB - PDF)

**First published:**

01/08/2025

[View](/hr/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_hr.pdf)

italiano (IT) (213.28 KB - PDF)

**First published:**

01/08/2025

[View](/it/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_it.pdf)

latviešu valoda (LV) (247.74 KB - PDF)

**First published:**

01/08/2025

[View](/lv/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_lv.pdf)

lietuvių kalba (LT) (235.03 KB - PDF)

**First published:**

01/08/2025

[View](/lt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_lt.pdf)

magyar (HU) (234.07 KB - PDF)

**First published:**

01/08/2025

[View](/hu/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_hu.pdf)

Malti (MT) (253.18 KB - PDF)

**First published:**

01/08/2025

[View](/mt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_mt.pdf)

Nederlands (NL) (215.57 KB - PDF)

**First published:**

01/08/2025

[View](/nl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_nl.pdf)

polski (PL) (252.62 KB - PDF)

**First published:**

01/08/2025

[View](/pl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_pl.pdf)

português (PT) (214.02 KB - PDF)

**First published:**

01/08/2025

[View](/pt/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_pt.pdf)

română (RO) (234.03 KB - PDF)

**First published:**

01/08/2025

[View](/ro/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_ro.pdf)

slovenčina (SK) (237.88 KB - PDF)

**First published:**

01/08/2025

[View](/sk/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sk.pdf)

slovenščina (SL) (246.52 KB - PDF)

**First published:**

01/08/2025

[View](/sl/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sl.pdf)

Suomi (FI) (212.76 KB - PDF)

**First published:**

01/08/2025

[View](/fi/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_fi.pdf)

svenska (SV) (215.07 KB - PDF)

**First published:**

01/08/2025

[View](/sv/documents/medication-error/rybelsus-risk-medication-error-due-new-tablet-formulation_sv.pdf)

#### More information on Rybelsus

- [Rybelsus - supply shortage](/en/medicines/human/shortages/rybelsus)
- [Rybelsus - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/rybelsus)
- [Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000513)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/01/2026

## Share this page

[Back to top](#main-content)